{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:06:35Z","timestamp":1789761995515,"version":"4.0.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Diseases Now"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.idnow.2026.105299","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:43:27Z","timestamp":1781077407000},"page":"105299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment duration of community-acquired pneumonia due to Legionella pneumophila: where do we stand?"],"prefix":"10.1016","volume":"56","author":[{"given":"Aur\u00e9lien","family":"Dinh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Saliba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Maulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Welker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.idnow.2026.105299_bb0005","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(21)00313-5","article-title":"Discontinuing \u03b2-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial","volume":"397","author":"Dinh","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.idnow.2026.105299_bb0010","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202507-1692ST","article-title":"Diagnosis and management of community-acquired pneumonia. An official American Thoracic Society clinical practice guideline","author":"Jones","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.idnow.2026.105299_bb0015","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0140-6736(15)60078-2","article-title":"Legionnaires\u2019 disease","volume":"387","author":"Cunha","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.idnow.2026.105299_bb0020","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s40121-022-00635-7","article-title":"Legionnaires\u2019 disease: update on diagnosis and treatment","volume":"11","author":"Viasus","year":"2022","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.idnow.2026.105299_bb0025","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1378\/chest.13-0162","article-title":"Importance of Legionella pneumophila in the etiology of severe community-acquired pneumonia in Santiago, Chile","volume":"145","author":"Arancibia","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.idnow.2026.105299_bb0030","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-018-3565-z","article-title":"Atypical pathogens in hospitalized patients with community-acquired pneumonia: a worldwide perspective","volume":"18","author":"Gramegna","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.idnow.2026.105299_bb0035","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.3201\/eid2011.131872","article-title":"Legionnaires\u2019 disease incidence and risk factors, New York, New York, USA, 2002\u20132011","volume":"20","author":"Farnham","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.idnow.2026.105299_bb0040","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1093\/cid\/ciy826","article-title":"Pneumococcal and Legionella urinary antigen tests in community-acquired pneumonia: prospective evaluation of indications for testing","volume":"68","author":"Bellew","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.idnow.2026.105299_bb0045","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious diseases society of america\/american thoracic society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idnow.2026.105299_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1469-0691.2011.03602.x","article-title":"Guidelines for the management of adult lower respiratory tract infections - summary","volume":"17","author":"Woodhead","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.idnow.2026.105299_bb0055","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4104\/pcrj.2010.00014","article-title":"Primary care summary of the British Thoracic Society Guidelines for the management of community acquired pneumonia in adults: 2009 update. Endorsed by the Royal College of General Practitioners and the Primary Care Respiratory Society UK","volume":"19","author":"Levy","year":"2010","journal-title":"Prim Care Respir J"},{"key":"10.1016\/j.idnow.2026.105299_bb0060","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/bmj.332.7554.1355","article-title":"Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study","volume":"332","author":"el Moussaoui","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.idnow.2026.105299_bb0065","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jamainternmed.2016.3633","article-title":"Duration of antibiotic treatment in community-acquired pneumonia: A Multicenter randomized clinical trial","volume":"176","author":"Uranga","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.idnow.2026.105299_bb0070","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3109\/00365549509047054","article-title":"Azithromycin for treatment of community acquired pneumonia caused by Legionella pneumophila: A retrospective study","volume":"27","author":"Kuzman","year":"1995","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.idnow.2026.105299_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106481","article-title":"Treatment of legionellosis including a single intravenous dose of 1.5 g azithromycin: 18-year experience at a tertiary care hospital","volume":"59","author":"Karer","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.idnow.2026.105299_bb0080","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1093\/jac\/dkx007","article-title":"Antimicrobial strategy for severe community-acquired legionnaires\u2019 disease: a multicentre retrospective observational study","volume":"72","author":"Cecchini","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idnow.2026.105299_bb0085","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciag085","article-title":"Legionella pneumonia in the modern era: clinical features and predictors of mortality","author":"Pulsipher","year":"2026","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idnow.2026.105299_bb0090","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.chest.2023.09.033","article-title":"Legionnaires disease in solid organ transplant recipients: A decade-long Nationwide study in France","volume":"165","author":"Thizy","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.idnow.2026.105299_bb0095","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.cmi.2017.02.030","article-title":"Levofloxacin versus azithromycin for treating legionella pneumonia: a propensity score analysis","volume":"23","author":"Garcia-Vidal","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.idnow.2026.105299_bb0100","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1183\/09031936.95.08030398","article-title":"Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia","volume":"8","author":"Rizzato","year":"1995","journal-title":"Eur Respir J"},{"key":"10.1016\/j.idnow.2026.105299_bb0105","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/jac\/dkh356","article-title":"Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia","volume":"54","author":"Tellier","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idnow.2026.105299_bb0110","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3109\/00365549409008639","article-title":"Three-day azithromycin compared with ten-day roxithromycin treatment of atypical pneumonia","volume":"26","author":"Sch\u00f6nwald","year":"1994","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.idnow.2026.105299_bb0115","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1086\/377539","article-title":"High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm","volume":"37","author":"Dunbar","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idnow.2026.105299_bb0120","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jama.279.18.1452","article-title":"Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines","volume":"279","author":"Halm","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.idnow.2026.105299_bb0125","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1473-3099(14)70713-3","article-title":"Epidemiology and clinical management of legionnaires\u2019 disease","volume":"14","author":"Phin","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.idnow.2026.105299_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175634","article-title":"Procalcitonin for selecting the antibiotic regimen in outpatients with low-risk community-acquired pneumonia using a rapid point-of-care testing: A single-arm clinical trial","volume":"12","author":"Masi\u00e1","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.idnow.2026.105299_bb0135","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.21037\/jtd.2016.08.30","volume":"8","author":"Zhao","year":"2016","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.idnow.2026.105299_bb0140","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1179\/joc.2008.20.1.77","article-title":"Efficacy and safety of azithromycin 1 g Once daily for 3 days in the treatment of community-acquired pneumonia: an open-label randomised comparison with amoxicillin-clavulanate 875\/125 mg twice daily for 7 days","volume":"20","author":"Paris","year":"2008","journal-title":"J Chemother"},{"key":"10.1016\/j.idnow.2026.105299_bb0145","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/jac\/dkm119","article-title":"Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study","volume":"60","author":"File","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idnow.2026.105299_bb0150","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1128\/AAC.49.10.4035-4041.2005","article-title":"Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia in adults","volume":"49","author":"D\u2019Ignazio","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idnow.2026.105299_bb0155","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1378\/chest.128.4.2230","article-title":"Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults","volume":"128","author":"Drehobl","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.idnow.2026.105299_bb0160","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijantimicag.2004.01.011","article-title":"Azithromycin versus comparative therapy for the treatment of community acquired pneumonia","volume":"24","author":"Rahav","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.idnow.2026.105299_bb0165","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1179\/joc.2004.16.1.102","article-title":"Comparative study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of community- acquired pneumonia in adults","volume":"16","author":"Sopena","year":"2004","journal-title":"J Chemother"},{"key":"10.1016\/j.idnow.2026.105299_bb0170","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/jac\/dkh356","article-title":"Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia","volume":"54","author":"Tellier","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idnow.2026.105299_bb0175","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1086\/377539","article-title":"High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm","volume":"37","author":"Dunbar","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idnow.2026.105299_bb0180","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/s100960050201","article-title":"Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia","volume":"17","author":"O\u2019Doherty","year":"1998","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"Suppl C","key":"10.1016\/j.idnow.2026.105299_bb0185","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/jac\/37.suppl_C.93","article-title":"Once-daily, 3-day azithromycin versus a three-times-daily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infections: results of a randomized, double-blind comparative study","volume":"37","author":"Gris","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idnow.2026.105299_bb0190","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3109\/00365549409008639","article-title":"Three-day azithromycin compared with ten-day roxithromycin treatment of atypical pneumonia","volume":"26","author":"Sch\u00f6nwald","year":"1994","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.idnow.2026.105299_bb0195","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/BF02310353","article-title":"Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia","volume":"14","author":"Bohte","year":"1995","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.idnow.2026.105299_bb0200","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1183\/09031936.95.08030398","article-title":"Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia","volume":"8","author":"Rizzato","year":"1995","journal-title":"Eur Respir J"},{"key":"10.1016\/j.idnow.2026.105299_bb0205","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/BF01975846","article-title":"Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia","volume":"10","author":"Kinasewitz","year":"1991","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.idnow.2026.105299_bb0210","first-page":"521","article-title":"Azithromycin versus josamycin: treatment of 89 cases of acute pneumonia","volume":"38","author":"Aprim null, Brion JP, Sedallian A, Le Noc P, Briffod J, Micoud M.","year":"1990","journal-title":"Pathol Biol (Paris)"},{"key":"10.1016\/j.idnow.2026.105299_bb0215","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/jac\/25.suppl_A.123","article-title":"Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias","volume":"25","author":"Sch\u00f6nwald","year":"1990","journal-title":"J Antimicrob Chemother"}],"container-title":["Infectious Diseases Now"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991926000564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991926000564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:16:11Z","timestamp":1789758971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666991926000564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2666991926000564"],"URL":"https:\/\/doi.org\/10.1016\/j.idnow.2026.105299","relation":{},"ISSN":["2666-9919"],"issn-type":[{"value":"2666-9919","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment duration of community-acquired pneumonia due to Legionella pneumophila: where do we stand?","name":"articletitle","label":"Article Title"},{"value":"Infectious Diseases Now","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idnow.2026.105299","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"105299"}}